ITUS Will Present Early Cancer Detection Data at ASCO-SITC Symposium on January 26

SAN JOSE, Calif., Jan. 22, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced again that it will be presenting data on its early cancer detection technology on January 26th at the American Society of Clinical Oncology-Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-oncology Symposium in San Francisco, CA.  

ITUS Logo (PRNewsfoto/ITUS Corporation)

The presentation abstract titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," will be released on January 22nd, however the underlying data will be kept confidential until the presentation on January 26th.  Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for ITUS' liquid biopsy technology.

The presentation will focus on ITUS' proprietary Cchek™ platform which couples immuno-oncology and artificial intelligence technologies to enable the detection of solid tumors from a blood sample. 

"We are looking forward to sharing our data with the scientific community," stated Dr. Amit Kumar, President and CEO of ITUS Corporation.  Dr. Kumar added, "This announcement repeats information we provided in our press release of December 6, 2017.  We are reissuing this information as we have had questions from shareholders indicating there is some confusion about when our data will be released.  As noted in this press release and the previous release, the ABSTRACT of the presentation will become public on January 22nd.  The data presentation will occur on January 26, 2018, after which the presentation will be publicly available.  We have provided instructions for requesting a copy of the presentation and we will begin emailing the poster to interested parties, beginning on January 29.  The presentation will be highly technical in nature, so on January 29, 2018, the Monday after the presentation, we will issue a press release summarizing the data and conclusions."

The symposium will be held on January 25-27, 2018, and will be attended by the leading scientific minds in the field of immuno-oncology from across the world.  All abstracts for the Symposium are currently confidential, but will be released by ASCO on January 22, 2018 at 5:00 PM EST on  To receive a copy of the presentation, please send your request to after January 26, 2018 and include your name, title, and contact information.

The ASCO-SITC Clinical Immuno-Oncology Symposium ( is a three-day meeting focused on clinical and translational research in immuno-oncology and the implications for clinical care.

ASCO ( was founded in 1964 and is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. 

SITC ( was found in 1984 and is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the CchekTM platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy.  Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.



Cision View original content with multimedia:

SOURCE ITUS Corporation